


IL-13 is a Dominant Cytokine in the Pathophysiology of AD^{1,2}

There are **three approved biologics** that target IL-13 signaling.³⁻⁵

Dupilumab³
Targets the IL-4 α Receptor

Lebrikizumab-Ibkz⁴
Targets the IL-13 Cytokine

Tralokinumab-Idrm⁵
Targets the IL-13 Cytokine



All three therapeutic antibodies differ in their binding affinity, dissociation constant, potency, and half-life.^{4,10,14-17}

To learn more about the role of IL-13 in AD, click below

Explore

Access US Prescribing Information at the following URLs:

DUPIXENT[®]: https://www.regeneron.com/downloads/dupilumab_fpi.pdf

EBGLYSS[®]: <https://pi.lilly.com/us/ebglyss-uspi.pdf>

ADBRY[®]: <https://www.leo-pharma.us/adbrypi>

AD=atopic dermatitis; **IL**=interleukin; **IL-4R α** =interleukin-4 receptor alpha;

IL-13R α 1=interleukin-13 receptor alpha 1; **IL-13R α 2**=interleukin-13 receptor alpha 2.

1. Tsoi LC, et al. *J Invest Dermatol.* 2019;139(7):1480-1489.
2. He H, et al. *J Allergy Clin Immunol.* 2021;147(1):199-212.
3. DUPIXENT[®] [US PI]. Tarrytown, NY, USA: Regeneron Pharmaceuticals, Inc., 2024.
4. EBGLYSS[®] [US PI] Indianapolis, IN, USA: Eli Lilly USA LLC, 2024.
5. ADBRY[®] [US PI]. Madison, NJ: LEO Pharma Inc., 2024.
6. Matsunaga K, et al. *Allergol Int.* 2020;69:187-196.
7. Kasaian MT, et al. *J Pharmacol Exp Ther.* 2008;325:882-892.
8. Simpson EL, et al. *J Am Acad Dermatol.* 2018;78(5):863-871.e11.
9. Gonçalves F, et al. *Drugs Context.* 2021;10:2021-1-7.
10. Ultsch M, et al. *J Mol Biol.* 2013;425(8).
11. Moyle M, et al. *Exp Dermatol.* 2019;28(7):756-768.
12. Lytvyn Y, Gooderham M. *Pharmaceutics.* 2023;15(2):568.
13. Bieber T. *Allergy.* 2020;75(1):54-62.
14. Okragly A, et al. *Dermatol Ther (Heidelb).* 2023;13(7):1535-1547.
15. Popovic B, et al. *J Mol Biol.* 2017;429(2):208-219.
16. Adtralza [SmPC]. Ballerup, Denmark: LEO Pharma A/S, 2021.
17. Dupixent EMA Assessment Report, 2017.

This content was commissioned by Lilly Medical and is intended to be used by HCPs for medical, scientific, and educational purposes.

Other product/company names mentioned herein are trademarks of their respective owners.

MMAT-01810 © 2026 LILLY USA, LLC. ALL RIGHTS RESERVED.